文章来源:MedRobot;编辑:Jacky
Reprint requirements: Please indicate the source of the article at the beginning of the article, which can be reprinted directly
MedRobot
At the end of 2023, MedRobot sorted out 27 financing events (corresponding to 25 companies) in the field of medical robotics this year. In this article, we will take stock of the companies and attach relevant reports (in order of financing time).
These financing events reflect the development trend of surgical robots and the value it brings to the clinic in 2023.
# Trends
High-precision and minimally invasive surgery: The development of surgical robots tends to be high-precision and minimally invasive, such as microsurgical robots and ophthalmic surgical robots, which are capable of performing extremely delicate surgical operations, reducing surgical trauma and recovery time.
Specialized application: It can be seen from the financing events that surgical robots are increasingly targeting specific specialties, such as cardiac interventional surgery, ophthalmic surgery, etc., which shows the adaptability and professional development of technology in different medical fields.
Integration of AI and machine Xi: The integration of AI and machine Xi is used to improve surgical precision and decision support, such as by analyzing large amounts of data to optimize surgical pathways or improve diagnostic accuracy.
Applications of Augmented Reality and Virtual Reality: Use AR and VR technologies to improve the accuracy of surgical planning, provide doctors with a more intuitive view of surgery, and conduct pre-operative simulation and training.
Globalization and commercialization: As the technology matures and the market is accepted, more companies are looking to expand into the global market, especially in developing countries.
# Clinical value
Improve surgical safety and accuracy: Surgical robots are able to perform high-precision operations, reducing errors and complications during surgery. Reduced recovery time and trauma: The use of minimally invasive surgical robots reduces incision size and surgical trauma, resulting in faster patient recovery. Empower doctors: Robotics expands doctors' surgical capabilities, allowing them to perform complex operations that were previously impossible to do manually. Improve surgical efficiency and reduce costs: In the long run, surgical robots can improve the efficiency of the operating room, reducing surgery time and recovery time, potentially reducing overall healthcare costs. This has been verified in the United States and other countries, and China still needs more practice and data accumulation.
Personalized and customized surgical plans: Using machine Xi and big data analysis, surgical robots can provide more personalized surgical plans that are optimized for the specific condition of patients.
# Angtai Micro Precision Financing Stage: Series A+ Product Type: General-purpose Microsurgical Robot
On January 12, 2023, Angtai Micro Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "Angtai Micro Precision") won another A+ round of financing of 10 million US dollars in less than 3 months after the completion of the last round of financing. This round of financing was exclusively invested by Temasek. The financing proceeds will be mainly used for the company's overseas registration, product research and development, team expansion, etc. Life Capital continues to act as the exclusive financial advisor for the company's financing. Company Introduction: Angtai Micro Precision is an innovative surgical robot company that takes minimally invasive microscopic technology as the starting point and aims to expand the boundaries of surgery. After more than ten years of technology accumulation, Ontai Micro has successfully developed a robot with no jitter operation throughout the process. The microsurgical robot developed by it has a high degree of refinement, which can perform high-spatial dimension operations in more refined scenarios, with more reusable times and stronger anti-tremor ability. It is reported that Angtai Micro Precision is promoting the research and development and certification of general-purpose microsurgical robots, ophthalmic surgical robots, and gastrointestinal endoscopic robots in China and the United States. Financing History:
# Huaquejing Financing Stage: Series A
Product Type: Rehabilitation Robot
On January 30, 2023, Shenzhen Huaquejing Medical Technology Co., Ltd. (hereinafter referred to as Huaquejing Medical), a leading international rehabilitation robot company, announced the completion of a Series A financing of tens of millions of yuan exclusively invested by Shenzhen Capital Group. The funds raised will be used for large-scale mass production, marketing and brand building, and continue to consolidate the leading position of product technology around the company's vision and mission.
Company Introduction:
Founded in July 2019, Huaquejing Medical Co., Ltd. is a national high-tech enterprise focusing on intelligent rehabilitation robots and intelligent rehabilitation medical solutions, with first-class rehabilitation medicine, engineering teams and expert teams from the Chinese Academy of Sciences, Harbin Institute of Technology and other institutions, and has accumulated more than 15 years of research and development experience in rehabilitation medicine, medical robots, artificial intelligence, virtual reality and other fields, has dozens of domestic and international invention patents, independent core technology is at the international leading level, and has developed upper limbs, Finger, cognitive, orthopedic and other intelligent rehabilitation robots
Rehabilitation Robot Company Completes Series A Financing|Inventory of Chinese Startup Companies
# Financing stage of Xianwei Vision: Angel Round
Product type: Ophthalmic surgery robot
On January 31, 2023, Xianwei Vision Technology (Nanjing) Co., Ltd. (hereinafter referred to as Xianwei Vision) announced the completion of nearly 50 million angel round financing. This round of financing is led by Shenzhen Dingxin Capital, followed by Nanjing Innovation Investment Group, and Zhishi Capital serves as the exclusive financial advisor, and the funds raised will be used for the R&D, production and industrialization of the ReLEx myopia correction surgical device.
Company Introduction:
In 2022, Xianwei Vision was co-founded by life optoelectronics scientists, ophthalmologists and serial entrepreneurs from Wuhan National Research Center for Optoelectronics, Huazhong University of Science and Technology. Focusing on the application research of femtosecond laser in the field of ophthalmic surgery and biomaterial processing, Xianwei Vision has R&D centers in Nanjing and Wuhan, and its first commercial product, the full femtosecond laser corneal refractive surgery device, originated from the technology transformation of Wuhan National Research Center for Optoelectronics of Huazhong University of Science and Technology.
# Dishi Medical Financing Stage: Pre-A Round/PreA+ Round Product Type: Ophthalmic Surgical Robot
On February 13, 2023, Dishi Medical completed tens of millions of yuan in Pre-A round of financing. This round of financing was led by Linear Capital and followed by Hillhouse Ventures. This round of funds is mainly used to accelerate the registration of NMPA Class III medical devices for ophthalmic surgical robots, and the research and development of pipelines such as microsurgical robots, as well as team expansion.
On July 10, 2023, Hangzhou Dishi Medical Biotechnology Co., Ltd. (hereinafter referred to as "Dishi Medical") announced the completion of tens of millions of yuan in PreA+ round of financing, which is the second round of financing completed by Dishi Medical in half a year.
Company Introduction:
Founded in July 2021, Dishi Medical is an ophthalmic medical device manufacturer, focusing on building an intelligent surgical medical system with ophthalmology and other microscopic assisted robots as the core and biotechnology as the core, and the main products are ophthalmic retinal surgery robots.
According to the company, the company takes the lead in achieving a motion accuracy of up to 3 microns with the technical advantages of personalized medical-engineering combination, multi-degree of freedom based on master-slave control, and original flexible mechanism, which is one of the highest in the world.
# Zhuodao Medical Financing Stage: Series B Product Type: Rehabilitation Robot
On February 15, 2023, Zhuodao Medical ®, a Chinese rehabilitation robot and intelligent rehabilitation innovation company, announced the completion of Series B financing, which was jointly led by Danlu Capital and Hengxu Capital, and followed by Shunwei Capital, with a total investment of more than 100 million yuan. This round of financing will accelerate the innovative R&D, market access and large-scale implementation of Zhuodao Medical ® in the field of intelligent rehabilitation comprehensive solutions. After nearly eight years of technological exploration and accumulation, Zhuodao Medical ® has built a systematic, framework, multidisciplinary integration technology platform and mature product R&D innovation system with completely independent intellectual property rights. The company's comprehensive intelligent rehabilitation solution - Zhuodao Smart Ark ®, covering OT and upper limb rehabilitation solutions, PT and lower limb rehabilitation solutions, including dozens of world-leading rehabilitation robots and intelligent software and hardware, many of which have been approved medical device registration certificates, and it is expected that within two years, the company will add more than ten innovative products to the market. Financing History:
# Mayo Magnetics Financing Stage: Series A/Series A+
Product type: Cardiac interventional surgery robot
On February 28, 2023, Meio CadiNav Medical, a cardiac interventional surgery robot company, completed its Series A financing. This round of financing is exclusively invested by Shaoxing Yuecheng District Urban Development Group. The proceeds from the financing will be used for a multi-center clinical trial of Mayo's core cardiomagnetic product, TITIAN's "Titian" atrial fibrillation interventional surgical robot.
On August 14, 2023, Mayo Magnetics announced the completion of the A+ round of financing led by Chuangrui Investment. This round of financing will help the company accelerate the clinical registration process of TITIAN's cardiac electrophysiology interventional device control system, and promote the research and development of a number of blockbuster surgical auxiliary control system product lines, so as to enhance the company's technical advantages in the field of cardiac ® interventional surgical assistance control system.
Company Introduction:
Founded in 2018, Mayo Cardiomagnet was co-founded by experts from the "Talent Introduction Program" in Zhejiang Province, the chief doctor of the Department of Clinical Cardiology, and the leading entrepreneurial team in Zhejiang Province. The company is committed to the research and development of new cardiac interventional surgery auxiliary control system products, focusing on independent innovation and research and development of cardiac surgery navigation technology, energy ablation platform and flexible interventional consumables, to provide cardiac electrophysiology and structural heart disease surgical treatment solutions. The company is headquartered in Shaoxing City, Zhejiang Province, and has core product R&D centers in Shanghai and Hangzhou.
In March 2023, with its excellent core technology, independent innovation ability, and hard-core product performance, the first "TITIAN Titian ® Cardiac Electrophysiology Interventional Device Control System" was approved to enter the national special review procedure for innovative medical devices, that is, the "green channel" for innovation.
Financing History:
The interventional cardiac surgery company completes Series A+
# Wansi Medical Financing Stage: Angel RoundProduct Type: Vascular Interventional Surgical Robot
On March 20, 2023, Beijing Wansi Medical Technology Co., Ltd. (hereinafter referred to as "Wansi Medical") announced the completion of an angel round of financing of 100 million yuan, jointly led by CAS Investment and Nuoyu Capital, with Qingke Capital as the exclusive long-term financial advisor. This round of financing will be used for technology research and development, new product iteration, team development and marketing.
Company Introduction:
Committed to the R&D and industrialization of vascular interventional surgical robots, Wansi Medical was founded by Professor Li Youxiang, a neurointerventional expert from Beijing Tiantan Hospital affiliated to Capital Medical University (hereinafter referred to as "Tiantan Hospital"), the company originated from the clinical, originated from the key R&D projects of the Ministry of Science and Technology, and has now achieved industrialization. The vascular interventional surgical robot developed by the company is the first product to enter the clinical stage in China, and has taken the lead in completing multi-center clinical trials in China. In March 2023, Vance Medical's "Cerebrovascular Interventional Surgery Assisted Operating System" was successfully approved by the NMPA, which is the first "Cerebrovascular Interventional Surgery Assisted Operating System" (robot) NMPA registration certificate in China.
# Surui Financing Stage: C3 Round Product Type: Laparoscopic Surgical Robot
On April 4, 2023, Surui, a Chinese single-port laparoscopic surgical robot company, reported that it had completed the C3 round of financing of hundreds of millions of yuan. This round of financing was led by Zhengxin Valley, with the full support of old shareholders such as Yuanxing Capital and SDIC China Merchants, and followed by Denuo Capital, Xinyi Investment and Sanya Cuihu. At the same time, it will further strengthen the company's global commercialization layout, comprehensively enhance the company's comprehensive competitive advantage in the field of surgical robots in the world, and work with top hospitals to continuously expand indications and application departments, collaborate and innovate, and create a new era of single-port.
Company Introduction:
Surui Robot is a high-tech medical device enterprise dedicated to independent research and development, production and sales of laparoscopic surgical robot systems, supporting surgical tools and consumables with the world's leading technological advantages. The company has core independent intellectual property rights and key core technologies of the whole chain, has nearly 600 intellectual property rights and applications worldwide, and has built a comprehensive independent intellectual property protection system, and has been supported and recognized by the Ministry of Industry and Information Technology, the Ministry of Science and Technology, Beijing Municipal Science and Technology Commission, Zhongguancun and other national and local governments at all levels, as well as many investment institutions.
Financing History:
# Jiaao Technology Financing Stage: Series A+ Product Type: Orthopedic Surgical Robot
On April 7, 2023, Shanghai Jiaao Information Technology Development Co., Ltd., a research and development company of intelligent surgical robots, announced the completion of tens of millions of yuan in Series A+ financing, which was led by Shenzhen Investment Holding Southern Fund. The proceeds of the financing will be mainly used to accelerate the research and development of new products, clinical registration, channel expansion and global market promotion of intelligent surgical robots.
Company Introduction:
Founded in 2017, the company focuses on the development of cutting-edge technology of medical surgical robots through close cooperation with medical and engineering cross-work with a number of top tertiary hospitals and universities, and has long been committed to creating a new generation of intelligent orthopedic surgical robots that meet the unique needs of the Chinese market, have high popularity and have the ultimate cost performance.
# Linyan Medical Financing Stage: Series A+ Product Type: Spine Surgery Robot
On April 14, 2023, Linyan Medical, a "human-machine combination" AR spine surgery navigation company, announced the completion of a 10-million-level A+ round of financing, which is mainly used for the launch of the navigation and positioning system Holonavi S for spine surgery and the continuous research and development of follow-up products.
The product has completed the registration clinical trial in September 2022, and 150 patients have been enrolled. The clinical results showed that the Spine Surgery Navigation and Positioning System Holonavi S improved the accuracy and safety of nail placement, and the quality and stability of spine surgery were better than those of conventional manual surgery, which could be used to assist doctors in orthopedic spine surgery.
Company Introduction:
Shanghai Linyan Medical is a high-tech company focusing on solving the needs of sinking medical institutions and the pain points of doctors' surgical aids, aiming to meet the needs of surgical quality consistency and cost-effective surgical diagnosis and treatment market through technological innovation. The core team has more than 10 years of experience in the transformation of production, education and research, taking the spine surgery navigation system with the highest surgical risk in orthopedics as the product entry point, taking root for nearly seven years, accumulating more than 70 domestic and foreign invention and utility model patents and 7 software copyrights, mainly distributed in the fields of augmented reality, artificial intelligence, surgical navigation and surgical robots.
# Tonglu Technology Financing Stage: Series A Product Type: Vascular Interventional Surgical Robot
On May 8, 2023, Shenzhen Tonglu Technology Co., Ltd. announced the successful completion of Series A financing (hereinafter referred to as "Tonglu Technology"), receiving tens of millions of yuan in investment. This round of financing was led by Oriental Fuhai and followed by well-known investment institutions such as Kangyu Capital. These investment institutions have deep strategic experience and industrial resources in the medical field, and will provide strong support for the future development of Tonglu Technology. Company Introduction:
Founded in December 2021 and headquartered in Nanshan, Shenzhen, Tonglu Technology is committed to developing a vascular interventional surgery robot platform and providing intelligent surgical solutions. Based on the existing core technical advantages and the geographical advantages of the Boston R&D center in the United States, the company's core team is composed of senior medical device industry practitioners and internationally renowned senior technical experts in the surgical robot, while deeply cultivating the field of vascular interventional surgery, developing an artificial intelligence system combining virtual and physical objects, and expanding the surgical robot to other application scenarios.
# Wealthking Precision
Financing Stage: Series D+ Product Type: Neurosurgical Robot
On May 12, 2023, Wealthking Precision announced the completion of a D+ round of financing of over 100 million yuan, with investors including Cinda Kunpeng, Shuimu Investment, Junshan Capital and Huiyu Investment, and the original shareholder Denuo Capital continued to increase its weight. At this point, the company announced the completion of the Series D financing round.
Company Introduction:
Founded in 2015, Sinoking Precision focuses on the neurosurgical robot industry. The company completed nearly 300 million yuan in Series D financing in December 2022, and at the same time completed the acquisition of Huake Hang Seng Company, forming a number of equipment pipelines such as neurosurgical robot series, neuronavigation series, miniature neurosurgical robot series, magnetic resonance monitoring laser ablation series, and neurosurgical planning software.
# Financing stage of Leadway Medical: Angel + round Product type: ophthalmic surgical robot
On May 17, 2023, Zhiwei Medical announced the completion of tens of millions of yuan in angel + round of financing, with investors in Danlu Capital and Beijing Medical Robot Industry Innovation Center.
Company Introduction:
Founded in 2022, the co-founder and chief executive officer (CEO) of the company is Mr. Ma Weimin, and the chief scientist is Professor Yang Yang of the Intelligent Machinery Design and Control Laboratory of Beihang University. It is reported that the company's ophthalmic surgical robot products have been iterated to the third generation, with good technical indicators, and at the same time have advantages in intelligent perception and control at the end of robot instruments. This financing will help Yiwei Medical to promote the product finalization and inspection of the third-generation ophthalmic surgical robot, and at the same time initiate the application for medical device registration certificates for other product pipelines under development, including dry eye treatment equipment.
Financing History:
# Aibo Hechuang Financing Stage: Series A Product Type: Vascular Interventional Surgical Robot
On June 1, 2023, Shenzhen Aibo Hechuang Medical Robot Co., Ltd. (hereinafter referred to as "Aibo Hechuang") announced the successful completion of a series A financing of 100 million yuan, injecting new vitality and hope into the field of vascular interventional surgical robots. The financing was led by Guozhong Capital, with the excess additional investment of the old shareholder Lenovo Venture Capital, and the continuous follow-up investment of Changling Capital, showing the confidence and optimism of investors in Aibo Medical Robot.
Aibo Hechuang will use the funds raised in this round of financing to accelerate the clinical enrollment of a new generation of pan-vascular interventional robots, promote the construction of an intelligent vascular interventional robot technology platform, and strengthen the comprehensive capacity building of the talent team.
Company Introduction:
As early as 2008, Professor Guo Shuxiang, the core founder of Aibo Hechuang and a foreign academician of the Japanese Academy of Engineering, led the team to successfully develop the world's first neurointerventional surgical robot in Japan. Since its establishment, Aibo Medical Robotics has focused on meeting the clinical needs of neurointervention, including neurointervention, as the focus of surgical robot research and development, and has taken the lead in developing a pan-vascular interventional robot with completely independent intellectual property rights in the world.
# Rob Medical
Financing stage: Series A
Product type: Digestive endoscopic surgical robot
On June 5, 2023, Shenzhen Robo Medical Technology Co., Ltd. (hereinafter referred to as "ROBO Medical") announced that it has recently completed tens of millions of yuan in Series A financing, which was led by Taikun Fund. The funds raised will be used for the clinical trial of "ROBO Medical" digestive endoscopic surgical robot products and the research and development of new products. Company introduction: ROBO Medical is a pioneer of surgical robots in the field of digestion, and has been committed to the technical research of flexible digestive endoscopic surgical robots. Financing History:
# Huajiang Medical Robot
Financing stage: Series A+
Product Type: Laparoscopic Surgical Robot
On June 26, 2023, Hangzhou Huajiang Medical Robot Co., Ltd. announced the completion of tens of millions of yuan in Series A+ financing, with investors such as Zhejiang News Group and Hangzhou Kai Group. This round of financing will be mainly used to strengthen the construction of the R&D team, enhance product R&D and innovation capabilities, accelerate the launch and market implementation of new products, and expand market share and brand influence. Company introduction: Founded in 2020, Huajiang Medical Robot has developed more than 10 products in the two major product systems of surgical robots and innovative devices around the three concepts of intelligence, convenience and inclusiveness. Among them, the intelligent reconfigurable laparoscopic surgical robot system can carry out different forms of intelligent combination and matching, so as to realize the clinical value of doctors who can flexibly choose the form of single-port/multi-port/human-machine collaborative surgery according to the needs of surgery. Financing History:
# Connosten
Funding Stage: Undisclosed
Product Type: Laparoscopic Surgical Robot
On June 30, 2023, Cornerstone Robotics, an innovative surgical robot company in China, announced the completion of a new round of financing of 800 million yuan. This round of financing has introduced a number of top investment institutions in the industry, including Daohe Technology Investment and Lenovo Venture Capital, and received additional investment from old shareholders Qingsong Capital, Meituan Longzhu, Qiming Venture Partners, Eli Lilly Asia Ventures, New World Development Group and Xianfeng K2VC. This round of financing will promote the company to accelerate the research and development of new surgical robots, clinical trials, registration and listing, and global promotion.
Company Introduction: Founded in September 2019, Conozten has a founding team of the world's leading medical surgical robot experts who have been deeply involved in the industry for decades. The company is committed to building a safe and efficient surgical robot platform, and has completed the construction of the underlying technology platform and industrialization platform, mastered the independent research and development, independent and controllable core technologies such as mechanical architecture, electrical architecture, software architecture, complex algorithms and visual image systems, and realized the multi-pipeline layout of soft tissue surgical robots and other major specialty surgical robots. In 2022, Conoxten Surgical Robot made important progress and became the first innovative surgical robot company in China to conduct clinical trials in the international market for the world. Raise 800 million! This domestic surgical robot goes global!
# Huakerun Biotech
Financing stage: Pre-C+ round
Product type: Orthopedic surgical robot
On July 14, 2023, Ningbo Huakerun Biotechnology Co., Ltd. (hereinafter referred to as "Huakerun") received tens of millions of yuan in Pre-C+ round of financing, which was invested by Shenzhen High-tech Investment and Haoyue Capital served as the exclusive financial advisor. The financing will be used to continue to advance the continuous R&D, clinical trials and commercialization of orthopedic microrobots and innovative orthopedic minimally invasive products. Company Introduction: Founded in 2011 and located in Hangzhou Bay New Area, the company has a layout of curved vertebroplasty system, bone cement for spine, spinal fixation, sports medicine, active equipment and consumables products, surgical robots and so on. As of the first half of 2023, the company has obtained 23 NMPA registration certificates, including 15 Class II registration certificates, 8 Class III registration certificates, and 7 products have obtained CE certification. It is reported that in the future, the company will maintain the speed of launching 5 new products per year. Financing History:
# Pounds
Financing stage: Series A+
Product Type: Hair Transplant Robot
On July 19, 2023, Kamp Kece (Shanghai) Intelligent Medical Technology Co., Ltd. (hereinafter referred to as "Kampong Ce") announced the completion of nearly 100 million yuan in Series A+ financing, and the funds raised will be used for product research and development, clinical certification, capacity enhancement and global promotion. Company Introduction: Founded in Shanghai in 2019, Kampong Ce Company is a company focusing on medical robots incubated by the robot system of Harbin Institute of Technology. The company's business scope includes: general projects: technology development, technology transfer, technical consulting, technical services, computer software and hardware development, industrial product design, computer and auxiliary equipment leasing, medical equipment leasing, sales of Class I medical devices in the field of medical technology, robotics and automation equipment. With in-depth clinical insight and profound technical accumulation, Kampong Ce independently developed the Hairo® hair transplant robot. Through stereo vision positioning technology, hair recognition, intelligent path planning, robotic arm force feedback protection, and real-time motion compensation, the controlled robotic arm can safely, efficiently and accurately complete hair follicle extraction surgery. Financing History:
# Chengtian Technology
Financing Stage: Strategic Investment
Product Type: Rehabilitation Robot
On August 28, 2023, Hangzhou Chengtian Technology Development Co., Ltd. (hereinafter referred to as Chengtian Technology), an exoskeleton technology company, announced the introduction of international investor Pappas Capital, and at the same time received continuous support from the old shareholder Yuhang Guotou. With the help of foreign capital, Chengtian Technology will accelerate the deployment of international business development, and significantly increase the introduction and investment of talents in the fields of R&D and marketing in the global market.
Company Introduction:
Founded in 2017, Hangzhou Chengtian Technology Development Co., Ltd. is a national high-tech enterprise with technological innovation as the core driving force. The company is committed to the research and development and application of exoskeleton robot technology, including core algorithms and core components, and currently focuses on the field of rehabilitation and elderly care, providing intelligent products and solutions for medical and health care institutions and individual users through the combination of human-computer interaction technology, artificial intelligence technology, data analysis and cloud computing.
Financing History:
Successful financing!New progress of exoskeleton robot company
# Relong Nokufu
Financing stage: Pre-B+ round
Product Type: Laparoscopic Surgical Robot
On August 30, 2023, Ronovo Surgical announced the completion of a Pre-B+ round of financing of nearly 200 million yuan, led by Newly Capital, followed by the new investor Yipu Capital, and all the company's old shareholders Eli Lilly Asia Ventures, Vivo Capital, Matrix Partners, GGV Capital, and LRI Jiangyuan Investment participated in this round of financing. The proceeds of the financing will be used for the company's product registration, clinical and R&D, and accelerate the implementation and brand promotion of modular surgical robots. Company Introduction:
Relong Novo is an innovative pioneer in the field of endoscopic surgical robots in China, and is committed to designing and developing innovative surgical robots for Chinese surgeons to meet the actual clinical needs of China. The company has gathered a team with rich experience in the design, R&D, manufacturing and commercialization of surgical robots, and the core team has worked for world-renowned medical device and robotics companies such as Intuitive Surgery, Auris Health, Kuka, Medtronic, Xerohui, and Norkang.
Financing History:
# Micro Eye Medical
Financing stage: Pre-A round
Product type: Ophthalmic surgery robot
On November 23, 2023, Guangzhou Micro Eye Medical Devices Co., Ltd. (hereinafter referred to as "Micro Eye Medical") completed tens of millions of yuan in Pre-A round of financing. This round of funds will be mainly used for the clinical research and industrialization of the company's core product, the micron-level high-precision ophthalmic surgical robot, and will also promote the sustainable development of MicroEye Medical in the whole chain of microscopic eye surgery.
Company Introduction:
Founded on December 14, 2020, Guangzhou Micro Eye Medical Devices Co., Ltd. is an innovative enterprise focusing on independent innovation and high-quality clinical application of ophthalmic microsurgical robots and related technologies, and is committed to creating high-precision and intelligent automation "femtosecond-like" equipment to assist complex fundus surgery.
Financing History:
Financing tens of millions of yuan!China's ophthalmic surgery robot has completed the Pre-A round!
# Haku Shikang
Financing stage: Series A
Product Type: Spine Surgery Robot
On November 30, 2023, Chongqing Boshikang Technology Co., Ltd. (hereinafter referred to as "Boshikang"), a manufacturer of optical and magnetic integrated navigation systems, has completed a round of financing. This round of funds will be used for the marketing of the company's core product sub-millimeter-level high-precision "optical-magnetic integrated spine surgery navigation system" and the research and development of follow-up new products, so as to promote the sustainable development of Bosconn in the field of precision and minimally invasive surgery. Company introduction: Founded in 2016 and located in the National High-tech Bio-Industrial Park of Chongqing Liangjiang New Area, Boshikang develops surgical instruments and surgical navigation equipment, and is committed to building a comprehensive innovative enterprise integrating "precision medical digital intelligent diagnosis and treatment platform + surgical instruments + consumables + medical technology services", focusing on spine, sports medicine, neurosurgery, otolaryngology and other fields, and providing "software + hardware + service" for precision minimally invasive surgery. Financing History:
# Really healthy
Financing stage: Series B+
Product type: Percutaneous puncture surgical robot
On December 5, 2023, it was reported that True Health (Guangdong Hengqin) Medical Technology Co., Ltd. (hereinafter referred to as "True Health"), a national high-tech enterprise in the field of medical artificial intelligence invested and introduced by Gree Group's production and investment company, completed a B+ round of financing of over 100 million yuan. It is understood that this round of financing will accelerate the R&D layout of True Health in the field of surgical robots, help enterprises increase technological innovation in surgical robots, core components, and artificial intelligence applications, and further enhance market share and comprehensive competitiveness. Company Introduction: Founded in 2018, True Health is a national high-tech enterprise focusing on the R&D and production services of surgical robots, and has successively obtained the first Class III medical device registration certificate and production license in the field of soft tissue puncture surgical robots, and the first "puncture surgery navigation and positioning system" in China. At present, the company has signed exclusive cooperation agreements with top medical institutions and well-known universities in the field of respiratory diseases in China, and related products have been successfully applied in clinical practice, and have set a number of "first" records.
# Langhe Medical
Financing stage: Series C
Product type: Surgical robot through natural orifice
On December 12, 2023, Langhe Medical completed a 100 million yuan Series C financing. This round of financing aims to expand the company's leading position in the field of flexible surgical robots through natural orifice, accelerate the clinical registration and commercialization of the company's key product portfolio, and provide world-leading solutions for various diseases, including lung cancer, that meet the needs of the Chinese market, for the benefit of doctors and patients. Company Introduction:
Langhe Medical is a medical surgical robot technology company, founded in 2015 in Shanghai Zero Bay Global Innovation and Entrepreneurship Cluster. The company has established close scientific research cooperation with Tsinghua University Minimally Invasive Diagnosis and Treatment and 3D Imaging Laboratory and Tsinghua University Medical Image Computing and Image-Guided Therapy Laboratory, and has made a comprehensive layout of a new generation of tumor minimally invasive interventional technologies such as flexible endoscopic surgical robots through natural orifice and over-the-horizon precise lung navigation, and has achieved fruitful results.
Financing History:
Over 100 million yuan! Flexible Surgical Robot Company Completes Series C Financing!